EDC4 enhances multi-drug chemosensitivity in pancreatic cancer via GR50-based profiling

Cheng Qin, Tianyu Li, Bangbo Zhao, Zeru Li, Yutong Zhao, Xiangyu Zhang, Yibo Xie, Yuying Yan, Jiashu Han, Qianqian Shao, Lin Chen, Weibin WangCancer 2025 · DOI

Abstract

PDAC cell lines exhibit distinct chemoresistance capabilities. EDC4 and its downstream targets MATN3 and SGCE play significant roles in PDAC multidrug chemoresistance, providing novel insights for treatment.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, largely due to the rapid development of resistance to standard chemotherapies like FOLFIRINOX and Gemcitabine/Nab-paclitaxel. A major hurdle in studying this resistance is the bias inherent in traditional IC50 measurements, which are often confounded by varying cell division rates. This study addresses this by using the growth-rate-adjusted metric (GR50) to identify genes that govern broad "multi-drug" sensitivity, identifying EDC4 as a critical regulator.

Methods

The researchers employed a multi-disciplinary approach to profile drug resistance across eight PDAC cell lines treated with five common agents: Gemcitabine, Albumin-bound Paclitaxel, Irinotecan, 5-FU, and Cisplatin.

Growth rate inhibition (GR) curves for five chemotherapeutic agents across various PDAC cell lines.

By utilizing GR50 instead of IC50, the team achieved a more accurate assessment of drug efficacy independent of baseline proliferation. They integrated RNA-seq data from the Cancer Cell Line Encyclopedia (CCLE) with clinical datasets (TCGA, GEO, and a PUMCH patient cohort) using LASSO and Random Forest regression to develop a chemosensitive risk signature. Functional validation was conducted via EDC4 knockdown and overexpression in 2D cultures and nude mice xenografts.

Key Results

Multi-Drug Sensitivity Profiling

The profiling revealed that certain cell lines, such as MIA PaCa-2 and BxPC-3, exhibited consistent sensitivity across all five tested drug classes, suggesting a shared mechanism for multi-drug vulnerability.

Venn diagram showing the overlap of drug sensitivity among PDAC cell lines, highlighting those with multi-drug sensitivity.

EDC4 as a Master Regulator

EDC4 was identified as a "good guy" gene that prevents resistance. High EDC4 expression is a marker of a chemosensitive phenotype and correlates with significantly longer overall survival in patients. As a component of the mRNA decapping complex, EDC4 acts as a "cleaner," degrading specific mRNAs like MATN3 and SGCE that would otherwise promote cancer stemness and extracellular matrix stiffness.

In Vivo and Clinical Impact

In mouse models, tumors overexpressing EDC4 were significantly smaller and lighter following chemotherapy compared to controls. Clinically, a 2-gene signature consisting of EDC4 and USP20 successfully predicted survival across multiple independent patient cohorts, demonstrating its potential as a robust prognostic tool.

Discussion and Conclusion

While 2D cultures cannot fully replicate the complex stroma of human pancreatic tumors, the identification of the EDC4-MATN3/SGCE axis provides a novel therapeutic target. EDC4 enhances chemosensitivity by clearing oncogenic transcripts, offering a promising strategy to sensitize PDAC to existing standard-of-care treatments. Future work will focus on refining clinical diagnostic thresholds and exploring interactions with KRAS mutations.

Summary updated

Abstract

PDAC cell lines exhibit distinct chemoresistance capabilities. EDC4 and its downstream targets MATN3 and SGCE play significant roles in PDAC multidrug chemoresistance, providing novel insights for treatment.
BibTeX
@inproceedings{qin2025edc,
  author = {Cheng Qin and Tianyu Li and Bangbo Zhao and Zeru Li and Yutong Zhao and Xiangyu Zhang and Yibo Xie and Yuying Yan and Jiashu Han and Qianqian Shao and Lin Chen and Weibin Wang},
  title = {{EDC4 enhances multi-drug chemosensitivity in pancreatic cancer via GR50-based profiling}},
  booktitle = {Cancer},
  year = {2025},
  doi = {10.1186/s12935-025-04000-9},
}
Figure